Kao shares rise on coronavirus antibody findings

Joint research with startup and Kitasato University opens door to new treatments

20200507 Kao

 Kao joins a number of other Japanese companies in the race to find a potential treatment for the deadly virus.

WATARU SUZUKI, Nikkei staff writer

TOKYO -- Shares of Japanese household goods maker Kao rose on Thursday after the company said it has jointly developed an antibody that suppresses new coronavirus infections.

The VHH antibody developed by the partnership is derived from camelids that are one-tenth the size of conventional antibodies and less costly to produce.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.